XOMA Corp logo

XOMA

XOMA Corp

$17.8

Earnings Summary

Revenue
$0.98Mn
PE Ratio
31.57

Highlights

Revenue:

XOMA Corp’s revenue jumped 9.1% since last year same period to $0.98Mn in the Q2 2022. On a quarterly growth basis, XOMA Corp has generated -68.36% fall in its revenue since last 3-months.

PE Ratio:

XOMA Corp’s price-to-earnings ratio after this Q2 2022 earnings stands at 31.57.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the XOMA Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.16
EPS Estimate Current Year
-0.16

Highlights

EPS Estimate Current Quarter:

XOMA Corp’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a 55.56% jump from last quarter’s estimates.

EPS Estimate Current Year:

XOMA Corp’s earning per share (EPS) estimates for the current year stand at -0.16.

Key Ratios

Key ratios of the XOMA Corp post its Q2 2022 earnings

Return on Assets (ROA)
0.08
Return on Equity (ROE)
0.14
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. XOMA Corp’s return on assets (ROA) stands at 0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. XOMA Corp’s return on equity (ROE) stands at 0.14.

Dividend Per Share (DPS):

XOMA Corp declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.36
-0.32
11.11%

Company Information

XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA's pioneering efforts in the discovery and development of antibody therapeutics. The Company's royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

Organisation
XOMA Corp
Headquarters
Berkeley, California, US
Employees
10
Industry
Health Technology